Risk Factors That Have Effect on Breast Cancer Recurrence in Rizgary Oncology Center in Erbil
DOI:
https://doi.org/10.56056/amj.2019.78Keywords:
Breast Cancer, Radiation therapy, RecurrenceAbstract
Background and objectives: Breast cancer is a heterogeneous disease with variations in clinical behavior and biological features that lead to variations in response to treatments and survival. The aim of this study was to look for the histopathological and therapeutic factors associated with breast cancer recurrence.
Methods: In this retrospective study, 100 locally recurrent or distant metastatic breast cancer cases were reviewed between 2008 -2016 at Rizgary Oncology Center in Erbil to find out the most important risk factors that have an effect on breast cancer recurrence.
Results: The current study revealed that grade of disease has a great effect on breast cancer recurrence when 64.9% of patients with grade III disease have had disease recurrence within the first 2 years from the date of diagnosis. Also, this study showed that, within the first two years from the date of diagnosis, 57.9% of stage III cases have had disease recurrence. Adding more, within the first two years, 36.4% of the triple-negative subtype and 41% of human epidermal growth factor receptor 2 enriched subtypes had disease recurrence within that period. Concerning the effect of delay in receiving adjuvant radiotherapy, 65.2% of those patients that were waited for more than two months to receive adjuvant radiotherapy had disease recurrence within the first two years.
Conclusions: Several factors have important effects on the disease recurrence like stage of the disease, grade, molecular subtypes, and delays in receiving adjuvant radiotherapy. All of them are independently causing earlier recurrence of breast cancer.
Downloads
References
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA: a cancer journal for clinicians. 2016; 66(1):7-30.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet?Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2):87-108.
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015; 136(5) E359-E86.
Hortobagyi GN, de la Garza Salazar J, Pritchard K, et al. The global breast cancer burden: variations in epidemiology and survival. Clinical breast cancer. 2005; 6(5):391-401.
De La Rochefordiere A, Campana F, Fenton J et al. Age as a prognostic factor in premenopausal breast carcinoma. The Lancet. 1993; 341(8852):1039-43.
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine. 2005; 353(17):1784-92.
Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiotherapy and Oncology. 2008; 87(1):3-16.
Gagliato Dde M, Gonzalez-Angulo AM, Lei X, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014; 32 (8): 735-44.
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63(1):181-7.
Sohrabi A, Sandoz J, Spratt JS, Polk HC. Recurrence of breast cancer: Obesity, tumor size, and axillary lymph node metastases. JAMA. 1980; 244(3):264-5.
Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clinical Medicine Insights: Pathology. 2015; 8:23-31.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology. 1991;19(5):403- 10.
Rakha EA, Reis-Filho JS, Baehner F, et al. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Research. 2010; 12(4):207.
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer sub-types based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clinical medicine & research. 2009; 7(1-2):4-13.
Klauber-DeMore N. Tumor biology of breast cancer in young women. Breast disease. 2006 ;23(1):9-15.
Al-Moundhri M, Al-Bahrani B, Pervez I, et al. The outcome of treatment of breast cancer in a developing country—Oman. The Breast. 2004;13(2):139-45.
Nissan A, Spira RM, Hamburger T, et al. Clinical profile of breast cancer in Arab and Jewish women in the Jerusalem area. The American Journal of Surgery. 2004;188(1):62-7.
El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC cancer. 2006; 6(1):194.
Ivshina AV, George J, Senko O et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer research. 2006; 66(21):10292-301.
Lundin J, Lundin M, Holli K et al. Omission of histologic grading from clinical decision making may result in overuse of adjuvant therapies in breast cancer: results from a nationwide study. Journal of clinical oncology. 2001;19(1):28-36.
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. Journal of Clinical Oncology. 2010; 28(10):1684-91.
Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast cancer research and treatment. 2012; 133(3):831- 41.
Dawood S, Hu R, Homes MD, et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast cancer research and treatment. 2011; 126(1):185-92.
Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer sub-types, and survival in the Carolina Breast Cancer Study. Jama. 2006; 295(21):2492-502.
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Journal of clinical oncology. 2005; 23(30):7703-20.
National Comprehensive Cancer Network. Breast Cancer (Version 3.2017). Available from https://www.nccn. org/professionals/physician_gls/pdf/breast.pdf. Accessed November 11, 2017.
Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer. 1992; 69(10):2496-501.
Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: American Society of clinical oncology, American Society for radiation oncology, and Society of surgical oncology-focused guideline update. Practical radiation oncology. 2016; 6(6):e219-34.
Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. Journal of clinical oncology. 2003; 21(3):555-63.
Benk V, Joseph L, Fortin P, et al. Effect of delay in initiating radiotherapy for patients with early-stage breast cancer. Clinical Oncology. 2004; 16(1):6-11.
Faculty of Radiation Oncology Quality Improvement Committee. Management of waiting lists in radiation oncology “Quality in the timeliness of patient care”–Version 2. The Royal Australian and New Zea- land College of Radiologists. 2013. Available from http://ranzcr.edu.au/ about/faculty?of?radiation?oncology/899?faculty?publication.
Downing A, Gilthorpe MS, Dodwell D, Lawrence G, Forman D. Waiting times for radiotherapy after breast-conserving surgery and the association with survival: a path analysis. Clinical Oncology. 2011; 23(7):442-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Sami Saleem Omar, Abdulmuniem Ahmed Mahdi, Jangi Shawkat Muhialdin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
